Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro Mix25 and insulin lispro Mix50

Paris Roach, Michael Trautmann, Vipin Arora, Bin Sun, James H. Anderson

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

The objective of this 6-month, open-label, randomized, two-period crossover study was to compare glycemic control when patients were treated with (1) 2 manufactured premixed insulin formulations containing insulin lispro and a novel insulin lispro-protamine formulation, neutral protamine lispro (NPL), and (2) 2 manufactured premixed human insulin formulations, human insulin 50/50 and human insulin 30/70. One hundred individuals, 37 with type 1 diabetes mellitus (12 females, 25 males; mean age, 39.4 years; mean body mass index [BMI], 24.8; mean duration of diabetes, 12.9 years) and 63 with type 2 diabetes mellitus (33 females, 30 males; mean age, 59.0 years; mean BMI, 28.4; mean duration of diabetes, 12.6 years), were treated with insulin lispro mixtures. Insulin lispro Mix50 (50% insulin lispro/50% NPL) and human insulin 50/50 (50% regular insulin/50% neutral protamine Hagedorn [NPH] insulin) were administered before breakfast; insulin lispro Mix25 (25% insulin lispro/75% NPL) and human insulin 30/70 (30% regular insulin/70% NPH) were administered before dinner. Blood glucose (BG), hypoglycemic episodes (hypoglycemic signs or symptoms or BG

Original languageEnglish (US)
Pages (from-to)523-534
Number of pages12
JournalClinical Therapeutics
Volume21
Issue number3
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Insulin Lispro
Protamines
Hypoglycemia
Blood Glucose
Insulin
Therapeutics
Hypoglycemic Agents
Body Mass Index
Biphasic Insulins
Isophane Insulin
Breakfast
Type 1 Diabetes Mellitus
Cross-Over Studies
Type 2 Diabetes Mellitus
Signs and Symptoms
Meals

Keywords

  • Hemoglobin A(1c)
  • Human insulin
  • Insulin lispro
  • Insulin mixtures
  • Nocturnal hypoglycemia

ASJC Scopus subject areas

  • Pharmacology

Cite this

Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro Mix25 and insulin lispro Mix50. / Roach, Paris; Trautmann, Michael; Arora, Vipin; Sun, Bin; Anderson, James H.

In: Clinical Therapeutics, Vol. 21, No. 3, 1999, p. 523-534.

Research output: Contribution to journalArticle

@article{18789ff7254d43d8b7681d634c688be7,
title = "Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro Mix25 and insulin lispro Mix50",
abstract = "The objective of this 6-month, open-label, randomized, two-period crossover study was to compare glycemic control when patients were treated with (1) 2 manufactured premixed insulin formulations containing insulin lispro and a novel insulin lispro-protamine formulation, neutral protamine lispro (NPL), and (2) 2 manufactured premixed human insulin formulations, human insulin 50/50 and human insulin 30/70. One hundred individuals, 37 with type 1 diabetes mellitus (12 females, 25 males; mean age, 39.4 years; mean body mass index [BMI], 24.8; mean duration of diabetes, 12.9 years) and 63 with type 2 diabetes mellitus (33 females, 30 males; mean age, 59.0 years; mean BMI, 28.4; mean duration of diabetes, 12.6 years), were treated with insulin lispro mixtures. Insulin lispro Mix50 (50{\%} insulin lispro/50{\%} NPL) and human insulin 50/50 (50{\%} regular insulin/50{\%} neutral protamine Hagedorn [NPH] insulin) were administered before breakfast; insulin lispro Mix25 (25{\%} insulin lispro/75{\%} NPL) and human insulin 30/70 (30{\%} regular insulin/70{\%} NPH) were administered before dinner. Blood glucose (BG), hypoglycemic episodes (hypoglycemic signs or symptoms or BG",
keywords = "Hemoglobin A(1c), Human insulin, Insulin lispro, Insulin mixtures, Nocturnal hypoglycemia",
author = "Paris Roach and Michael Trautmann and Vipin Arora and Bin Sun and Anderson, {James H.}",
year = "1999",
doi = "10.1016/S0149-2918(00)88307-1",
language = "English (US)",
volume = "21",
pages = "523--534",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "3",

}

TY - JOUR

T1 - Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro Mix25 and insulin lispro Mix50

AU - Roach, Paris

AU - Trautmann, Michael

AU - Arora, Vipin

AU - Sun, Bin

AU - Anderson, James H.

PY - 1999

Y1 - 1999

N2 - The objective of this 6-month, open-label, randomized, two-period crossover study was to compare glycemic control when patients were treated with (1) 2 manufactured premixed insulin formulations containing insulin lispro and a novel insulin lispro-protamine formulation, neutral protamine lispro (NPL), and (2) 2 manufactured premixed human insulin formulations, human insulin 50/50 and human insulin 30/70. One hundred individuals, 37 with type 1 diabetes mellitus (12 females, 25 males; mean age, 39.4 years; mean body mass index [BMI], 24.8; mean duration of diabetes, 12.9 years) and 63 with type 2 diabetes mellitus (33 females, 30 males; mean age, 59.0 years; mean BMI, 28.4; mean duration of diabetes, 12.6 years), were treated with insulin lispro mixtures. Insulin lispro Mix50 (50% insulin lispro/50% NPL) and human insulin 50/50 (50% regular insulin/50% neutral protamine Hagedorn [NPH] insulin) were administered before breakfast; insulin lispro Mix25 (25% insulin lispro/75% NPL) and human insulin 30/70 (30% regular insulin/70% NPH) were administered before dinner. Blood glucose (BG), hypoglycemic episodes (hypoglycemic signs or symptoms or BG

AB - The objective of this 6-month, open-label, randomized, two-period crossover study was to compare glycemic control when patients were treated with (1) 2 manufactured premixed insulin formulations containing insulin lispro and a novel insulin lispro-protamine formulation, neutral protamine lispro (NPL), and (2) 2 manufactured premixed human insulin formulations, human insulin 50/50 and human insulin 30/70. One hundred individuals, 37 with type 1 diabetes mellitus (12 females, 25 males; mean age, 39.4 years; mean body mass index [BMI], 24.8; mean duration of diabetes, 12.9 years) and 63 with type 2 diabetes mellitus (33 females, 30 males; mean age, 59.0 years; mean BMI, 28.4; mean duration of diabetes, 12.6 years), were treated with insulin lispro mixtures. Insulin lispro Mix50 (50% insulin lispro/50% NPL) and human insulin 50/50 (50% regular insulin/50% neutral protamine Hagedorn [NPH] insulin) were administered before breakfast; insulin lispro Mix25 (25% insulin lispro/75% NPL) and human insulin 30/70 (30% regular insulin/70% NPH) were administered before dinner. Blood glucose (BG), hypoglycemic episodes (hypoglycemic signs or symptoms or BG

KW - Hemoglobin A(1c)

KW - Human insulin

KW - Insulin lispro

KW - Insulin mixtures

KW - Nocturnal hypoglycemia

UR - http://www.scopus.com/inward/record.url?scp=0032951336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032951336&partnerID=8YFLogxK

U2 - 10.1016/S0149-2918(00)88307-1

DO - 10.1016/S0149-2918(00)88307-1

M3 - Article

VL - 21

SP - 523

EP - 534

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 3

ER -